ClinicalTrials.gg
CompletedNCT02561923Updated Feb 3, 2025

A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants

A Phase 1 interventional study of Rivaroxaban and Tranexamic acid in Healthy, sponsored by Janssen Scientific Affairs, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2016, 10 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the independent effects of both a 4-Factor prothrombin complex concentrate (PCC) - (Kcentra) and Tranexamic acid (TXA) on the bleeding parameters (bleeding duration and blood volume) following a punch biopsy, in addition to assessing their effects on the anticoagulant/pharmacodynamic (prothrombin time and endogenous thrombin potential) changes induced by rivaroxaban at steady state, to better understand their potential role in bleeding reversal.

Read the detailed description

This is a 2 part, single center study to be conducted in healthy men and women. Part 1 (open-label) consists of Screening Phase (within 28 days before admission into the study center on Day -1), followed by a 3 day treatment period and a follow-up visit on Day 8. A single oral 20 milligram (mg) dose of rivaroxaban will be administered on Day 1. Pharmacokinetic (PK), pharmacodynamics (PD), and punch biopsy parameters will be assessed. Part 2 (double-blind) consists of Screening Phase (within 28 days before admission into the study center on Day -1), followed by a 8 day treatment period (Day -1 to Day 7) and a follow-up visit on Day 11. Rivaroxaban (20 mg every 12 hrs) will be administered on Days 1 through 3 and single 20 mg dose will be given on the morning of Day 4. A single dose of either 4-factor PCC, TXA or saline (Placebo) will be administered in a randomized, blinded fashion on Day 4. PK, PD, Exploratory Bio-markers and punch biopsy parameters will be assessed. Participants' safety will be monitored throughout the study.

02

Conditions studied

  • Healthy

Keywords

  • Healthy
  • Rivaroxaban
  • XARELTO
03

In context

Lead sponsor

Janssen Scientific Affairs, LLC is the lead sponsor of 41 studies on the registry; 2 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (weight kilogram [kg]/height\^2 meters [m]\^2) between 18 and 30 kg/m2 (inclusive), and body weight between 50 and 100 kg;
  • Participants must have coagulation test results of (PT) and a partial thromboplastin time (PTT) within normal limits at Screening
  • Must have normal renal function, as per medical history
  • If a woman, must be (no spontaneous menses for at least 2 years), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of (eg, double-barrier method or male partner sterilization) before entry and throughout the study. (Note: combined hormonal contraception should not be used)
  • Non-smoker (Note: subjects should not have used nicotine-containing products within 30 days before study drug administration)
  • If a woman, must have a negative serum Beta-human chorionic gonadotropin (hCG)] pregnancy test at Screening; and a negative serum pregnancy test on Day -1 of the study
  • If a man, must agree to use adequate contraception method as deemed appropriate by the investigator (eg, vasectomy, double-barrier, partner using effective contraception) and to not donate sperm during the study and for 3 months after receiving the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • History of or current medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease (including history of definite myocardial infarction, cerebrovascular accident, percutaneous transluminal coronary angioplasty or coronary artery bypass graft within 6 months before the Screening visit, or a previous intracranial hemorrhage at any time, known history of lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, neurologic or psychiatric disease, seizure disorder, infection, skin disease, or any other illness that the investigator considers should exclude the subject or that could interfere with the interpretation of the study results
  • Participants with any history of thrombosis, inherited or acquired thrombophilia, bleeding diathesis or coagulopathy (including any abnormal bleeding or blood dyscrasias), hematologic disease, clinically significant hemorrhagic disorder, excessive bruising, bleeding from nose or gums or known disorders with increased bleeding risk (eg, acute gastritis, acute peptic ulcer), serious bleeding including gastrointestinal bleeding requiring hospitalization, intracranial bleeding of any type, or uncontrollable postoperative bleeding
  • Known antithrombin III, Protein C, or Protein S deficiency, Factor V Leiden or prothrombin gene 20210 mutation, anticardiolipin (immunoglobulin G [IgG] and immunoglobulin M [IgM]) or antiphospholipid antibodies, or family history of unexplained thrombotic disorders
  • History of intracranial tumor or aneurysm or known abdominal aneurysm
  • Clinically significant abnormal physical examination, vital signs or 12-lead electrocardigram [] at Screening or at admission to the study center on Day -1, as deemed appropriate by the investigator. This would include: resting pulse >100 or \<40 beats per min, blood pressure systolic >140 or \<90 millimeters per mercuric level [mmHg], and diastolic blood pressure > 90 or \< 50 mmHg (pulse and blood pressure measurements should be taken in a supine position, after resting for at least 5 minutes)
  • Participants for whom surface blood vessels could not be visualized, or who have a history of likelihood of forming keloid scars
  • Use of any prescription or nonprescription medication (including antiplatelet, anticoagulants, aspirin, non-steroidal anti-inflammatory drugs, vitamins and herbal supplements), within 7 days before the first dose of the study drug is scheduled
  • Known allergy to the study drugs or any of the of the formulations
  • Unable to swallow solid, oral dosage forms whole with the aid of water (participants may not chew, divide, dissolve, or crush the study drug)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    Rivaroxaban

    Participants will be administered a single 20 milligram (mg) dose of rivaroxaban orally on Day 1 in Part 1.

    Drug: Rivaroxaban

  • Experimental
    Rivaroxaban plus tranexamic acid (TXA)

    Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, tranexamic acid (TXA) 1.0 gram (g) - (over 10 mins) intravenously administered on Day 4 in Part 2.

    Drug: Rivaroxaban · Drug: Tranexamic acid

  • Experimental
    Rivaroxaban plus Kcentra

    Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, participants will be randomized to receive a single dose of Kcentra (a 4-factor PCC), 50 international units per kilogram (IU/kg), intravenously administered (maximum rate of 210 \[international units per minute\] IU/min) on Day 4 in Part 2.

    Drug: Rivaroxaban · Drug: Kcentra, a 4-factor PCC

  • Experimental
    Rivaroxaban plus Saline

    Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, saline \[Kcentra saline control or TXA saline control\] on Day 4 in Part 2.

    Drug: Rivaroxaban · Drug: Saline

Interventions

  • A single dose of 20 milligram (mg) of rivaroxaban orally will be administered to participants on Day 1 in part 1 and through day 1 and 3 with a final 20 mg dose administered on the morning of Day 4 in part 2.

  • 1.0 g single dose of tranexamic acid (TXA), intravenously administered (over 10 mins) on Day 4.

  • DrugKcentra, a 4-factor PCC

    Kcentra, a 4-factor PCC, 50 IU/kg, single dose, intravenously administered (maximum rate of 210 \[international units\] IU/min) on Day 4.

  • DrugSaline

    Saline \[Kcentra saline control or TXA saline control\] on Day 4.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Blood Volume in Part 1

    Volume of blood (BV) collected after a punch biopsy is performed.

    Time frame: Day-1 (Baseline) and 4 hour (hr) postdose on Day 1

  2. Change From Baseline in Bleeding Duration in Part 1

    Bleeding duration (BD) after a punch biopsy is performed.

    Time frame: Day-1 (Baseline) and 4 hr postdose on Day 1

  3. Mean Change in Thrombin Generation Assay (TGA) - Endogenous Thrombin Potential (ETP) Lag-time in Part 2

    The thrombin generation assay (TGA) is based on the premise that measurements of thrombin generation are indicative of the overall coagulating capacity of the individual. The data derived from the thrombography can be used to determine the ETP, which in turn provides a functional assessment of the overall clotting cascade. Change in lag time (time required until thrombin is generated) will be observed.

    Time frame: Predose (Baseline) and up to 72 hrs postdose on Day 4

  4. Mean Change in Thrombin Generation Assay (TGA) - Endogenous Thrombin Potential (ETP) Peak in Part 2

    The thrombin generation assay (TGA) is based on the premise that measurements of thrombin generation are indicative of the overall coagulating capacity of the individual. The data derived from the thrombography can be used to determine the ETP, which in turn provides a functional assessment of the overall clotting cascade. Change in peak (the maximal effect on thrombin generation) will be observed.

    Time frame: Predose (Baseline) and 72 hours postdose on Day 4

  5. Mean Change in Thrombin Generation Assay (TGA) - Endogenous Thrombin Potential (ETP) Time to Peak in Part 2

    The thrombin generation assay (TGA) is based on the premise that measurements of thrombin generation are indicative of the overall coagulating capacity of the individual. The data derived from the thrombography can be used to determine the ETP, which in turn provides a functional assessment of the overall clotting cascade. Change in time-to-peak (time required to reach maximal effect on thrombin generation) will be observed.

    Time frame: Predose (Baseline) and 72 hours postdose on Day 4

  6. Mean Change in Thrombin Generation Assay (TGA) - Endogenous Thrombin Potential (ETP) Area Under Curve (AUC) in Part 2

    The thrombin generation assay (TGA) is based on the premise that measurements of thrombin generation are indicative of the overall coagulating capacity of the individual. The data derived from the thrombography can be used to determine the ETP, which in turn provides a functional assessment of the overall clotting cascade. Change in AUC (the overall effect on thrombin generation) will be observed.

    Time frame: Predose (Baseline) up to 72 hours on Day 4

  7. Mean Change in Prothrombin Time (PT) in Part 2

    Prothrombin Time is a global clotting test that is used for the assessment of the extrinsic pathway of the blood coagulation cascade.

    Time frame: Predose (Baseline) up to 72 hours on Day 4

  8. Change From Baseline in Blood Volume in Part 2

    Time frame: Predose (Baseline) and 72 hours on Day 4

  9. Change From Baseline in Bleeding Duration in Part 2

    Time frame: Predose (Baseline) and 72 hours on Day 4

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) in Part 1

    Time frame: Predose and up to 24 hrs postdose on Day 1

  2. Time to Maximum Observed Plasma Concentration in Part 1 (Tmax)

    Time frame: Predose and up to 24 hrs post-dose

  3. Area under Plasma Concentration Time Curve From Time 0 to 24 in Part 1 (AUC [0 TO 24]

    Time frame: Predose and up to 24 hrs postdose on Day 1

  4. Maximum Observed Plasma Concentration (Cmax) in Part 2

    Time frame: Predose and up to 72 hrs postdose on Day 4

  5. Minimum Observed Plasma Concentration (Cmin) in Part 2

    Time frame: Predose Days 1 to 4

  6. Time to Maximum Observed Plasma Concentration (Tmax) in Part 2

    Time frame: Predose and up to 72 hrs postdose on Day 4

  7. Area under plasma concentration time curve during the dosing interval (AUCtau) in Part 2

    Time frame: Predose and up to 24 hours

  8. Mean Change in Thrombin Generation Assay (TGA) Endogenous Thrombin Potential (ETP) Lag-time in Part 1

    The thrombin generation assay (TGA) is based on the premise that measurements of thrombin generation are indicative of the overall coagulating capacity of the individual. The data derived from the thrombography can be used to determine the ETP, which in turn provides a functional assessment of the overall clotting cascade. Change in lag time (time required until thrombin is generated) will be observed.

    Time frame: Predose (Baseline) up to 24 hours on Day 1

  9. Mean Change in Thrombin Generation Assay (TGA) Endogenous Thrombin Potential (ETP) Peak in Part 1

    The thrombin generation assay (TGA) is based on the premise that measurements of thrombin generation are indicative of the overall coagulating capacity of the individual. The data derived from the thrombography can be used to determine the ETP, which in turn provides a functional assessment of the overall clotting cascade. Change in peak (the maximal effect on thrombin generation) will be observed.

    Time frame: Predose (Baseline) up to 24 hours on Day 1

  10. Mean Change in Thrombin Generation Assay (TGA) Endogenous Thrombin Potential (ETP) Time to Peak in Part 1

    The thrombin generation assay (TGA) is based on the premise that measurements of thrombin generation are indicative of the overall coagulating capacity of the individual. The data derived from the thrombography can be used to determine the ETP, which in turn provides a functional assessment of the overall clotting cascade. Change in time-to-peak (time required to reach maximal effect on thrombin generation) will be observed.

    Time frame: Predose (Baseline) up to 24 hours on Day 1

  11. Mean Change in Thrombin Generation Assay (TGA) Endogenous Thrombin Potential (ETP) Area Under Curve (AUC) in Part 1

    The thrombin generation assay (TGA) is based on the premise that measurements of thrombin generation are indicative of the overall coagulating capacity of the individual. The data derived from the thrombography can be used to determine the ETP, which in turn provides a functional assessment of the overall clotting cascade. Change in AUC (the overall effect on thrombin generation) will be observed.

    Time frame: Predose (Baseline) up to 24 hours on Day 1

  12. Mean Change in Prothrombin Time (PT) in Part 1

    Prothrombin Time is a global clotting test that is used for the assessment of the extrinsic pathway of the blood coagulation cascade.

    Time frame: Predose (Baseline) up to 24 hours on Day 1

  13. Trough Plasma Concentration (Ctrough) in Part 2

    Ctrough is the trough plasma concentration before dosing or at the end of the dosing interval of any dose other than the first dose.

    Time frame: Predose and up to 72 hrs postdose on Day 4

  14. Number of Participants With Adverse Events as a Measure of Safety and Tolerability

    An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: Up to 37 Days (Part 1) and Up to 40 Days (Part 2)

07

Study locations

1 site
  • Overland Park, Kansas, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Jun 2016, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2015
First posted
Sep 28, 2015
StartActual
Aug 27, 2015
Primary completionActual
Jun 17, 2016
CompletionActual
Jun 17, 2016
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02561923
Collaborators
Bayer
Responsible party
Sponsor
First posted
Sep 28, 2015
Start date
Aug 27, 2015
Primary completion
Jun 17, 2016
Completion
Jun 17, 2016
Last update
Feb 3, 2025

Study contacts

Janssen Scientific Affairs, LLC Clinical Trial
study director · Janssen Scientific Affairs, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion